全文获取类型
收费全文 | 3834篇 |
免费 | 231篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 22篇 |
儿科学 | 124篇 |
妇产科学 | 82篇 |
基础医学 | 623篇 |
口腔科学 | 40篇 |
临床医学 | 368篇 |
内科学 | 983篇 |
皮肤病学 | 75篇 |
神经病学 | 457篇 |
特种医学 | 76篇 |
外科学 | 295篇 |
综合类 | 6篇 |
预防医学 | 156篇 |
眼科学 | 37篇 |
药学 | 315篇 |
中国医学 | 2篇 |
肿瘤学 | 425篇 |
出版年
2023年 | 18篇 |
2022年 | 62篇 |
2021年 | 97篇 |
2020年 | 56篇 |
2019年 | 80篇 |
2018年 | 85篇 |
2017年 | 74篇 |
2016年 | 93篇 |
2015年 | 99篇 |
2014年 | 154篇 |
2013年 | 182篇 |
2012年 | 303篇 |
2011年 | 324篇 |
2010年 | 181篇 |
2009年 | 150篇 |
2008年 | 246篇 |
2007年 | 264篇 |
2006年 | 232篇 |
2005年 | 250篇 |
2004年 | 210篇 |
2003年 | 209篇 |
2002年 | 190篇 |
2001年 | 34篇 |
2000年 | 29篇 |
1999年 | 29篇 |
1998年 | 55篇 |
1997年 | 33篇 |
1996年 | 28篇 |
1995年 | 34篇 |
1994年 | 15篇 |
1993年 | 11篇 |
1992年 | 23篇 |
1991年 | 16篇 |
1990年 | 22篇 |
1989年 | 16篇 |
1988年 | 14篇 |
1987年 | 19篇 |
1986年 | 16篇 |
1985年 | 11篇 |
1984年 | 15篇 |
1983年 | 16篇 |
1982年 | 12篇 |
1981年 | 6篇 |
1980年 | 10篇 |
1979年 | 8篇 |
1973年 | 5篇 |
1971年 | 5篇 |
1970年 | 6篇 |
1969年 | 5篇 |
1966年 | 6篇 |
排序方式: 共有4086条查询结果,搜索用时 15 毫秒
91.
92.
93.
94.
Chiellini G Erba P Carnicelli V Manfredi C Frascarelli S Ghelardoni S Mariani G Zucchi R 《The Journal of endocrinology》2012,213(3):223-230
3-Iodothyronamine (T1AM) is a novel chemical messenger, structurally related to thyroid hormone, able to interact with G protein-coupled receptors known as trace amine-associated receptors (TAARs). Little is known about the physiological role of T1AM. In this prospective, we synthesized [125I]-T1AM and explored its distribution in mouse after injecting in the tail vein at a physiological concentration (0.3?nM). The expression of the nine TAAR subtypes was evaluated by quantitative real-time PCR. [125I]-T1AM was taken up by each organ. A significant increase in tissue vs blood concentration occurred in gallbladder, stomach, intestine, liver, and kidney. Tissue radioactivity decreased exponentially over time, consistent with biliary and urinary excretion, and after 24?h, 75% of the residual radioactivity was detected in liver, muscle, and adipose tissue. TAARs were expressed only at trace amounts in most of the tissues, the exceptions being TAAR1 in stomach and testis and TAAR8 in intestine, spleen, and testis. Thus, while T1AM has a systemic distribution, TAARs are only expressed in certain tissues suggesting that other high-affinity molecular targets besides TAARs exist. 相似文献
95.
Andreassi MG Adlerstein D Carpeggiani C Shehi E Fantinato S Ghezzi E Botto N Coceani M L'abbate A 《Atherosclerosis》2012,223(2):409-415
AimsHigh-risk single nucleotide polymorphisms (SNPs) have been recently identified as risk factors for ischemic heart disease in large epidemiological and genome-wide association studies. However, their influence on prognosis remains uncertain. The aim of the study was to investigate the impact of previously identified SNPs and their joint effects in a genetic score (GS) on Major Adverse Cardiac Events (MACEs).Methods and resultsHigh-throughput genotyping for 48 high-risk SNPs was performed in 498 patients (432 males; 57.4 ± 8.3 years) who were followed-up for 6.9 ± 3.4 years. First MACE-coronary-related death, nonfatal myocardial infarction, or myocardial revascularization- was the endpoint taken into consideration. A GS was obtained by summing the number of significant high-risk alleles associated to MACEs.One-hundred and nineteen patients (24%) had a MACE. The hazard ratio (HR) for SNPs with a significant difference in cumulative survival were: APOC3 -482C > T (HR = 1.7, 95% CI 1.01–3.0), MTHFR (HR = 1.5, 95% CI 1.02–2.2), NADHPH oxidase- p22-PHOX C242T (HR = 1.9, 95% CI 1.2–2.8), PON-2 (HR = 0.2, 95% CI 0.1–0.8), and SELP (HR = 0.6, 95% CI 0.4–0.8). The resulting GS predicted a 25% risk for MACEs per risk allele (HR = 1.25, 95% CI 1.1–1.4, p = 0.001). The highest HR for MACEs was found in patients in the top tertile (HR = 3.0, 95% CI 1.4–6.7, p = 0.0005) of the GS compared with those in the bottom tertile.ConclusionOur findings show that high-risk SNPs may be used to create a useful GS that predicts MACEs in a secondary prevention setting, which in turn allows a better risk stratification. 相似文献
96.
97.
98.
99.
100.
De Nicola S Aghemo A Rumi MG Galmozzi E Valenti L Soffredini R De Francesco R Prati GM D'Ambrosio R Cheroni C Donato MF Colombo M 《Hepatology (Baltimore, Md.)》2012,55(2):336-342
Single nucleotide polymorphisms (SNPs) near the interleukin 28B (IL28B) region are the strongest baseline predictors of a sustained virologic response (SVR) to peg-interferon (PegIFN) and ribavirin (Rbv) in patients with hepatitis C virus (HCV) genotype 1 infection. Whether this holds true for HCV-4 patients too is unknown. The aim was to investigate the predictive power of the rs12979860 IL28B SNP for a response to Peg-IFN and Rbv in HCV-4 patients. All HCV-4 patients consecutively treated between September 2004 and June 2010 with PegIFN and Rbv at two liver centers at the Maggiore Hospital Milan (Italy) underwent TaqMan SNP Genotyping assays for testing rs12979860 genotype. Of 112 treated patients (98 males, 75 of Egyptian descent, 26 with cirrhosis) 103 were included in the final analysis; five discontinued treatment for nonvirologic reasons and four did not consent to genetic testing. Twenty-four (23%) were genotype CC, 65 (63%) CT, and 14 (14%) TT. Overall, 50 (49%) achieved an SVR: 21 (88%) CC patients versus 29 (37%) CT/TT (P < 0.0001). CC patients more often had a rapid virologic response (RVR) than CT/TT patients (12, 50% versus 23, 29%; P = 0.08), while also showing lower relapse rates (0% [0/21] versus 36% [16/45] P = 0.0013). In non-RVR patients, SVR rates were higher in CC than CT/TT patients (9 [75%] versus 13 [23%] P = 0.001). By logistic regression, the IL28B rs12979860 CC genotype was an independent predictor of SVR with an odds ratio of 8.0 (95% confidence interval 2.00-32.01; P = 0.003). CONCLUSION: The IL28B rs12979860 SNP may have an added value in the treatment algorithm of HCV-4 patients because it is the strongest predictor of an SVR to PegIFN/Rbv therapy. 相似文献